Daniel B Costa

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

S. Kobayashi, D. Costa, Kim-Son H Nguyen, 2009, Clinical lung cancer.

Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells

Christian Steidl, Daniel G Tenen, Frank Rosenbauer, 2006, Nature Genetics.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Adnan Majid, A. Majid, S. Kobayashi, 2018, Lung cancer.

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

S. Kobayashi, D. Costa, Susumu Kobayashi, 2012, The Lancet. Oncology.

β-catenin contributes to lung tumor development induced by EGFR mutations.

Kwok-Kin Wong, Yuichiro Hayashi, Kenzo Soejima, 2014, Cancer research.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

S. Kobayashi, D. Costa, Susumu Kobayashi, 2014, Lung cancer.

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

S. Kobayashi, D. Costa, Weiwei Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.